Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

781. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK Davies A, Vardeva K, Loze JY, L'Italien GJ, Sennfalt K, van Baardewijk M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of 12 treatment sequences for the management of stable schizophrenia. The authors concluded that aripiprazole followed by risperidone was the most cost-effective treatment sequence for these patients in the UK. Despite limited reporting of the effectiveness data, the methods were valid

2008 NHS Economic Evaluation Database.

782. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Full Text available with Trip Pro

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated. We aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode (...) schizophrenia.We did an open randomised controlled trial of haloperidol versus second-generation antipsychotic drugs in 50 sites, in 14 countries. Eligible patients were aged 18-40 years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder. 498 patients were randomly assigned by a web-based online system to haloperidol (1-4 mg per day; n=103), amisulpride (200-800 mg per day; n=104), olanzapine (5-20 mg per day; n=105), quetiapine (200-750 mg per day; n=104

2008 Lancet Controlled trial quality: predicted high

783. Incidence of schizophrenia lower in people with type I diabetes

Incidence of schizophrenia lower in people with type I diabetes Incidence of schizophrenia lower in people with type I diabetes | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Incidence of schizophrenia lower in people with type I diabetes Article Text Prevalence Incidence of schizophrenia lower in people with type I diabetes Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please

2008 Evidence-Based Mental Health

784. Maternal exposure to death of a first degree relative during first trimester of pregnancy increases risk of schizophrenia in offspring

Maternal exposure to death of a first degree relative during first trimester of pregnancy increases risk of schizophrenia in offspring Maternal exposure to death of a first degree relative during first trimester of pregnancy increases risk of schizophrenia in offspring | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) of schizophrenia in offspring Article Text Aetiology Maternal exposure to death of a first degree relative during first trimester of pregnancy increases risk of schizophrenia in offspring Statistics from Altmetric.com QUESTION Question: Does exposure of pregnant women to adverse life events increase risk of schizophrenia in offspring? People: 688 146 women giving birth in Denmark between 1 January 1973 and 30 June 1995 and identified through the Medical Birth Registry. Civil Registration records

2008 Evidence-Based Mental Health

785. Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness

Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness Article Text Therapeutics Review: Paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness Statistics from

2008 Evidence-Based Mental Health

786. Review: Cognitive remediation improves cognitive functioning in schizophrenia

Review: Cognitive remediation improves cognitive functioning in schizophrenia Review: Cognitive remediation improves cognitive functioning in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Cognitive remediation improves cognitive functioning in schizophrenia Article Text Therapeutics Review: Cognitive remediation improves cognitive functioning in schizophrenia Statistics from Altmetric.com QUESTION Question

2008 Evidence-Based Mental Health

787. Hereditary multiple exostoses and schizophrenia Full Text available with Trip Pro

Hereditary multiple exostoses and schizophrenia I report a case of a patient who suffered schizophrenia and multiple exostoses and argue the possible role of EXT gene and nearly chromosomal loci in further genetic investigations related to schizophrenia.

2008 Indian journal of human genetics

788. Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks

Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who

2007 Evidence-Based Mental Health

789. Lithium for schizophrenia. Full Text available with Trip Pro

Lithium for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, among them lithium.To review the effects of lithium for the treatment of schizophrenia and schizophrenia-like psychoses.We searched the Cochrane Schizophrenia Group's register (November 2006). This register is compiled by methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE (...) of schizophrenia and/or schizophrenia-like psychoses.We extracted data independently. For homogenous dichotomous data we calculated random effects, relative risk (RR), 95% confidence intervals (CI) and, where appropriate, numbers needed to treat (NNT) on an intention-to-treat basis. For continuous data, we calculated weighted mean differences (WMD).The update search in 2006 did not detect further studies that met our inclusion criteria. The review thus still includes 20 studies with a total of 611 participants

2007 Cochrane

790. Antipsychotic medication for childhood-onset schizophrenia. Full Text available with Trip Pro

Antipsychotic medication for childhood-onset schizophrenia. Childhood-onset schizophrenia is schizophrenia with onset prior to the age of 13 years. Although it is rare, people who suffer from schizophrenia at an early age appear to have a clinically severe form of the illness with poor long-term prognosis. Antipsychotic medication is one way of managing this rare but serious mental illness.To examine the effects of antipsychotic medication for childhood-onset schizophrenia.We searched (...) the Cochrane Schizophrenia Group Trials Register (November 2006 and February 2007), inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies and authors of trials for additional information.We included all randomised clinical trials involving children and young people with a diagnosis of childhood onset schizophrenia (i.e. with a diagnosis of schizophrenia before the age of 13) comparing any antipsychotic drug with another antipsychotic or placebo.We

2007 Cochrane

791. Testosterone for schizophrenia. (Abstract)

Testosterone for schizophrenia. Recently, sex hormones such as estrogens and testosterone or its derivatives have been the focus of interest for treatment of persistent symptoms associated with schizophrenia.To review the effects of dehydroepiandrosterone (DHEA)/testosterone as adjunctive therapy to standard antipsychotic drugs.We searched the Cochrane Schizophrenia Group Trials Register (January 2007).We included all clinical randomised trials comparing DHEA/testosterone plus standard (...) unaffected by use of DHEA (n=55, 1 RCT, WMD 6.20 CI -1.4 to 13.8).Results are inconclusive with most outcomes being either non-significant or producing contradictory findings. Currently, adjunctive DHEA should remain an experimental treatment for people with schizophrenia.

2007 Cochrane

792. Carbamazepine for schizophrenia. Full Text available with Trip Pro

Carbamazepine for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.To evaluate the effects of carbamazepine and its derivatives for the treatment of schizophrenia and related psychoses.For the original version we searched Biological Abstracts (1980-2001), The Cochrane Library (Issue 3, 2001 (...) ), The Cochrane Schizophrenia Group's Register of Trials (December 2001), EMBASE (1980-2001), MEDLINE (1966-2001), PsycLIT (1886-2001) and PSYNDEX (1974-2001). For the current update we searched the Cochrane Schizophrenia Group's Register of Trials in March 2005 and in December 2006. We also inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies and authors for additional data.We included all randomised controlled trials comparing carbamazepine

2007 Cochrane

793. Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia

Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Article Text Therapeutics Adding sarcosine, but not D

2007 Evidence-Based Mental Health

794. Problem solving skills for schizophrenia. Full Text available with Trip Pro

Problem solving skills for schizophrenia. The severe and long-lasting symptoms of schizophrenia are often the cause of severe disability. Environmental stress such as life events and the practical problems people face in their daily can worsen the symptoms of schizophrenia. Deficits in problem solving skills in people with schizophrenia affect their independent and interpersonal functioning and impair their quality of life. As a result, therapies such as problem solving therapy have been (...) developed to improve problem solving skills for people with schizophrenia.To review the effectiveness of problem solving therapy compared with other comparable therapies or routine care for those with schizophrenia.We searched the Cochrane Schizophrenia Group's Register (September 2006), which is based on regular searches of BIOSIS, CENTRAL, CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials.We included all clinical randomised trials comparing

2007 Cochrane

795. Epilepsy or a family history of epilepsy increases the risk of schizophrenia or schizophrenia-like psychosis Full Text available with Trip Pro

Epilepsy or a family history of epilepsy increases the risk of schizophrenia or schizophrenia-like psychosis Epilepsy or a family history of epilepsy increases the risk of schizophrenia or schizophrenia-like psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Epilepsy or a family history of epilepsy increases the risk of schizophrenia or schizophrenia-like psychosis Article Text Aetiology Epilepsy or a family history of epilepsy

2007 Evidence-Based Mental Health

796. About 30% of men with schizophrenia or schizoaffective disorders have obsessive-compulsive symptoms

About 30% of men with schizophrenia or schizoaffective disorders have obsessive-compulsive symptoms About 30% of men with schizophrenia or schizoaffective disorders have obsessive-compulsive symptoms | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here About 30% of men with schizophrenia or schizoaffective disorders have obsessive-compulsive symptoms Article Text Prevalence About 30% of men with schizophrenia or schizoaffective disorders

2007 Evidence-Based Mental Health

797. Mother and baby units for schizophrenia. (Abstract)

Mother and baby units for schizophrenia. Mother and baby units (MBUs) are recommended, in the UK, as an optimal site for treating post partum psychoses. Naturalistic studies suggest poor outcomes for mothers and their children if admission is needed during the first year after birth, but the evidence for the effectiveness of MBUs in addressing the problems faced by both mothers with mental illness and their babies is unclear.To review the effects of mother and baby units for mothers (...) with schizophrenia or psychoses needing admission during the first year after giving birth, and their children, in comparison to standard care on a ward without a mother and baby unit.We undertook electronic searches of the Cochrane Schizophrenia Group's Register (June 2006).We included all randomised clinical trials comparing placement on a mother and baby unit compared to any other standard care without attachment to such a unit.If data were available we would have independently extracted data and analysed

2007 Cochrane

798. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia

Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia Obradovic M, Mrhar A, Kos M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the cost-effectiveness of alternative outpatient treatments based on antipsychotic drugs for adults with chronic schizophrenia in Slovenia. The authors concluded that, among second-generation antipsychotics, olanzapine and risperidone were the most cost-effective strategies from the perspective of the health care system. Overall, the study methodology was good, with extensive information

2007 NHS Economic Evaluation Database.

799. Cognitive remediation therapy in schizophrenia: randomised controlled trial

Cognitive remediation therapy in schizophrenia: randomised controlled trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

800. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis

Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis Sepehry A A, Potvin S, Elie R, Stip E CRD summary This review found that selective serotonin re-uptake inhibitor augmentation does (...) not improve the negative symptoms of schizophrenia. These findings are likely to be reliable. Authors' objectives To investigate the effect of selective serotonin re-uptake inhibitor (SSRI) add-on therapy on the negative symptoms of schizophrenia. Searching MEDLINE, PsycINFO (1967 to 2005) and Current Contents (1993 to 2005) were searched; the keywords were reported. Published review articles and reference lists were screened for additional relevant studies. Pharmaceutical companies were contacted

2007 DARE.